Chromadex (NASDAQ:CDXC) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.
A number of other research analysts also recently issued reports on CDXC. ValuEngine raised shares of Chromadex from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. HC Wainwright reaffirmed a “buy” rating on shares of Chromadex in a research report on Monday, September 11th. Ladenburg Thalmann Financial Services initiated coverage on shares of Chromadex in a research report on Monday, September 25th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research report on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $7.13.
Shares of Chromadex (NASDAQ:CDXC) traded down $0.23 during trading on Friday, hitting $6.02. 446,730 shares of the stock were exchanged, compared to its average volume of 314,240. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.12 and a current ratio of 5.03. Chromadex has a 52-week low of $2.26 and a 52-week high of $7.24. The stock has a market cap of $337.02, a P/E ratio of -43.00 and a beta of 1.38.
A number of large investors have recently added to or reduced their stakes in the business. Granite Investment Partners LLC grew its position in Chromadex by 5.7% during the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after purchasing an additional 13,599 shares during the last quarter. Thompson Davis & CO. Inc. purchased a new stake in Chromadex during the 3rd quarter worth approximately $128,000. Goldman Sachs Group Inc. grew its position in Chromadex by 870.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in Chromadex during the 2nd quarter worth approximately $168,000. 6.79% of the stock is currently owned by institutional investors.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.